Mechanisms of action and chemical-biological interactions between ozone and body compartments: A critical appraisal of the different administration routes

Current Drug Therapy

Volumn 4, Issue 3, 2009, Pages 159-173

  Bocci, Velio ^a   Zanardi, Iacopo ^a   Michaeli, David ^b   Travagli, Valter ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Antioxidants; Hormesis; Oxidative stress; Ozone tolerance; Ozonetherapy; Vascular diseases

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; CORTICOSTEROID; HYDROGEN PEROXIDE; OXYGEN; OZONE; PLACEBO; PROSTANOID; REACTIVE OXYGEN METABOLITE; STEROID; TEMOZOLOMIDE; UNSATURATED FATTY ACID;

ATOPIC DERMATITIS; BLINDNESS; BRADYCARDIA; CELLULITIS; CHEMICAL INTERACTION; CHRONIC DISEASE; CHRONIC STRESS; CLINICAL TRIAL; DETOXIFICATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ERYTHROCYTE; EXTRACORPOREAL CIRCULATION; FAINTNESS; GAS EXCHANGE; GLIOBLASTOMA; HEART ARREST; HERPES ZOSTER; HUMAN; HYDROPHOBICITY; HYPOTENSION; IMMUNE SYSTEM; INTERVERTEBRAL DISK HERNIA; ISCHEMIA; LIPID PEROXIDATION; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; MESOTHELIOMA; MYDRIASIS; NONHUMAN; OXIDATIVE STRESS; OXYGEN SATURATION; OXYGEN THERAPY; OZONATION; OZONE THERAPY; PAIN; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; UPREGULATION; URINARY EXCRETION; VASCULAR DISEASE;

EID: 73449108070     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488509789055045     Document Type: Review

References (121)

1. Stoker G. The surgical uses of ozone. Lancet 1916; 188: 712.
2. Wolff HH. Die Behandlung peripherer Durchblutungsstörungen mit Ozon. Erfahr Hk 1974; 23: 181-4.
3. Jonas WB. Alternative medicine - learning from the past, examining the present, advancing to the future. JAMA 1998; 280: 1616-8.
4. Bocci V, Valacchi G, Corradeschi F, et al. Studies on the biological effects of ozone: 7. Generation of reactive oxygen species (ROS) after exposure of human blood to ozone. J Biol Regul Homeost Agents 1998; 12: 67-75.
5. Shinriki N, Suzuki T, Takama K, et al. Susceptibilities of plasma antioxidants and erythrocyte constituents to low levels of ozone. Haematologia 1998; 29: 229-39.
6. Bocci V, Aldinucci C. Biochemical modifications induced in human blood by oxygenation-ozonation. J Biochem Mol Toxicol 2006; 20: 133-8.
7. Bocci V. Scientific and medical aspects of ozone therapy. State of the art. Arch Med Res 2006; 37: 425-35.
8. Bocci V. The case for oxygen-ozonetherapy. Br J Biomed Sci 2007; 64: 44-9.
9. Bocci V, Borrelli E, Travagli V, Zanardi I. The ozone paradox: Ozone is a strong oxidant as well as a medical drug. Med Res Rev 2009; 29: 646-82.
10. Bocci V. Oxygen-Ozone therapy. A critical evaluation. Dordrecht, The Netherlands, Kluwer Academic Publishers 2002.
11. Bocci V. Ozone. A new medical drug. Dordrecht, The Netherlands, Springer 2005.
12. Calabrese EJ. Paradigm lost, paradigm found: the re-emergence of hormesis as a fundamental dose response model in the toxicological sciences. Environ Pollut 2005; 138: 379-411.
13. Nakao A, Sugimoto R, Billiar TR, McCurry KR. Therapeutic antioxidant medical gas. J Clin Biochem Nutr 2009; 44: 1-13.
14. Bell ML, McDermott A, Zeger SL, Samet JM, Dominici F. Ozone and short-term mortality in 95 US urban communities, 1987-2000. JAMA 2004; 292: 2372-8.
15. Jerrett M, Burnett RT, Pope CA 3rd, et al. Long-term ozone exposure and mortality. N Engl J Med 2009; 360: 1085-95.
16. Last JA, Gohil K, Mathrani VC, Kenyon NJ. Systemic responses to inhaled ozone in mice: cachexia and down-regulation of liver xenobiotic metabolizing genes. Toxicol Appl Pharmacol 2005; 208: 117-26.
17. Bocci V. Is it true that ozone is always toxic? The end of a dogma. Toxicol Appl Pharmacol 2006; 216: 493-504.
18. Battino R, Rettici TR, Tominaga T. The solubility of oxygen and ozone in liquids. J Phys Chem Ref Data 1983; 12: 163-78.
19. Cross CE, Reznick AZ, Packer L, Davis PA, Suzuki YJ, Halliwell B. Oxidative damage to human plasma proteins by ozone. Free Radic Res Commun 1992; 15: 347-52.
20. Carballal S, Radi R, Kirk MC, Barnes S, Freeman BA, Alvarez B. Sulfenic acid formation in human serum albumin by hydrogen peroxide and peroxynitrite. Biochemistry 2003; 42: 9906-14.
21. Carballal S, Alvarez B, Turell L, Botti H, Freeman BA, Radi R. Sulfenic acid in human serum albumin. Amino Acids 2007; 32: 543-51.
22. Pryor WA, Das B, Church DF. The ozonation of unsaturated fatty acids: aldehydes and hydrogen peroxide as products and possible mediators of ozone toxicity. Chem Res Toxicol 1991; 4: 341-8.
23. Enami S, Hoffmann MR, Colussi AJ. Ozone oxidizes glutathione to a sulfonic acid. Chem Res Toxicol 2009; 22: 35-40.
24. Larini A, Bocci V. Albumin is the most effective antioxidant during human plasma and blood ozonization. Rivista Italiana di Ossigeno-Ozonoterapia 2004; 3: 15-24.
25. Sugio S, Kashima A, Mochizuki S, Noda M, Kobayashi K. Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng 1999; 12: 439-46.
26. Aldini G, Gamberoni L, Orioli M, et al. Mass spectrometric characterization of covalent modification of human serum albumin by 4-hydroxy-trans-2-nonenal. J Mass Spectrom 2006; 41: 1149-61.
27. Aldini G, Vistoli G, Regazzoni L, et al. Albumin is the main nucleophilic target of human plasma: A protective role against proatherogenic electrophilic reactive carbonyl species? Chem Res Toxicol 2008; 21: 824-35.
28. Van der Vliet A, O'Neil CA, Eiserich JP, Cross CE. Oxidative damage to extracellular fluids by ozone and possible protective effects of thiols. Arch Biochem Biophys 1995; 321: 43-50.
29. Halliwell B. Antioxidants in human health and disease. Annu Rev Nutr 1996; 16: 33-50.
30. Kermani S, Ben-Jebria A, Ultman JS. Kinetics of ozone reaction with uric acid, ascorbic acid, and glutathione at physiologically relevant conditions. Arch Biochem Biophys 2006; 451: 8-16.
31. 131I-albumin polymers. Arch Biochem Biophys 1967; 120: 621-7.
32. Ogasawara Y, Namai T, Togawa T, Ishii K. Formation of albumin dimers induced by exposure to peroxides in human plasma: a possible biomarker for oxidative stress. Biochem Biophys Res Commun 2006; 340: 353-8.
33. Bocci V. Catabolism of plasma proteins. In: Allison AC Ed, Structure and function of plasma proteins. New York, Plenum Press 1976; 163-88.
34. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993; 84: 407-12.
35. Travagli V, Zanardi I, Bocci V. A realistic evaluation of the action of ozone on whole human blood. Int J Biol Macromol 2006; 39: 317-20.
36. Travagli V, Zanardi I, Silvietti A, Bocci V. A physicochemical investigation on the effects of ozone on blood. Int J Biol Macromol 2007; 41: 504-11.
37. Goldstein BD, Balchum OJ. Effect of ozone on lipid peroxidation in the red blood cell. Exp Biol Med 1967; 126: 356-8.
38. Cataldo F, Gentilini L. Chemical kinetics measurements on the reaction between blood and ozone. Int J Biol Macromol 2005; 36: 61-5.
39. Esterbauer H, Zollner H, Lang J. Metabolism of the lipid peroxidation product 4-hydroxynonenal by isolated hepatocytes and by liver cytosolic fractions. Biochem J 1985; 228: 363-73.
40. Barrera G, Toaldo C, Pizzimenti S, et al. The role of PPAR ligands in controlling growth-related gene expression and their interaction with lipoperoxidation products. PPAR Res 2008; 2008: 524671.
41. Poli G, Schaur RJ, Siems WG, Leonarduzzi G. 4-Hydroxynonenal: a membrane lipid oxidation product of medicinal interest. Med Res Rev 2008; 28: 569-631.
42. Valacchi G, Bocci V. Studies on the biological effects of ozone: 11. Release of factors from human endothelial cells. Mediators Inflamm 2000; 9: 271-6.
43. Bocci V, Valacchi G, Corradeschi F, Fanetti G. Studies on the biological effects of ozone: 8. Effects on the total antioxidant status and on interleukin-8 production. Mediators Inflamm 1998; 7: 313-7.
44. 2 gradients across biomembranes. FEBS Lett 2000; 475: 121-6.
45. Stone JR, Collins T. The role of hydrogen peroxide in endothelial proliferative responses. Endothelium 2002; 9: 231-8.
46. Stone JR, Yang S. Hydrogen peroxide: a signaling messenger. Antioxid Redox Signal 2006; 8: 243-70.
47. Bocci V, Luzzi E, Corradeschi F, Paulesu L, Di Stefano A. Studies on the biological effects of ozone: 3. An attempt to define conditions for optimal induction of cytokines. Lymphokine Cytokine Res 1993; 12: 121-6.
48. Bocci V, Valacchi G, Rossi R, et al. Studies on the biological effects of ozone: 9. Effects of ozone on human platelets. Platelets 1999; 10: 110-6.
49. Mendiratta S, Qu ZC, May JM. Erythrocyte ascorbate recycling: antioxidant effects in blood. Free Radic Biol Med 1998; 24: 789-97.
50. Mendiratta S, Qu ZC, May JM. Enzyme-dependent ascorbate recycling in human erythrocytes: role of thioredoxin reductase. Free Radic Biol Med 1998; 25: 221-8.
51. Bocci V. Does ozone therapy normalize the cellular redox balance? Implications for therapy of human immunodeficiency virus infection and several other diseases. Med Hypotheses 1996; 46: 150-4.
52. Bocci V. Ozone as a bioregulator. Pharmacology and toxicology of ozonetherapy today. J Biol Regul Homeost Agents 1996; 10: 31-53.
53. Petersen DR, Doorn JA. Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med 2004; 37: 937-45.
54. Siems W, Grune T. Intracellular metabolism of 4-hydroxynonenal. Mol Aspects Med 2003; 24: 167-75.
55. Awasthi YC, Ansari GA, Awasthi S. Regulation of 4-hydroxynonenal mediated signaling by glutathione S-transferase. Methods Enzymol 2005; 401: 379-407.
56. Alary J, Geuraud F, Cravedi JP. Fate of 4-hydroxynonenal in vivo: disposition and metabolic pathways. Mol Aspects Med 2003; 24: 177-87.
57. Dianzani MU. 4-Hydroxynonenal and cell signalling. Free Radic Res 1998; 28: 553-60.
58. Claiborne A, Yeh JI, Mallett TC, et al. Protein-sulfenic acids: diverse roles for an unlikely player in enzyme catalysis and redox regulation. Biochemistry 1999; 38: 15407-16.
59. Bocci V, Aldinucci C, Mosci F, Carraro F, Valacchi G. Ozonation of human blood induces a remarkable upregulation of heme oxygenase-1 and heat stress protein-70. Mediators Inflamm 2007; 2007: 26785.
60. Pittler MH, Armstrong NC, Cox A, Collier PM, Hart A, Ernst E. Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis. Br J Derm 2003; 148: 307-13.
61. Torre-Amione G, Anker SD, Bourge RC, et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet 2008; 371: 228-36.
62. Sliwa K, Ansari AA. Immunosuppression as therapy for congestive heart failure. Lancet 2008; 371: 184-6.
63. Fildes JE, Shaw SM, Yonan N, Williams SG. Non-specific immunomodulation in chronic heart failure. Lancet 2008; 37: 2083.
64. Bocci V. The failure of the ACCLAIM trial is due to an irrational technology. Int J Cardiol 2008, in press. DOI:10.1016/j.ijcard.2008.10.001.
65. Bocci V, Di Paolo N, Garosi G, et al. Ozonation of blood during extracorporeal circulation. I. Rationale, methodology and preliminary studies. Int J Artif Organs 1999; 22: 645-51.
66. Travagli V, Zanardi I, Gabbrielli A, Paccagnini E, Bocci V. Are dialysis devices usable as ozone gas exchangers? Artif Organs 2009, in press. DOI:10.1111/j.1525-1594.2009.00767.x.
67. Bocci V, Zanardi I, Travagli V, Di Paolo N. Oxygenation-ozonation of blood during extracorporeal circulation: in vitro efficiency of a new gas exchange device. Artif Organs 2007; 31: 743-8.
68. Bocci V, Travagli V, Zanardi I, Di Paolo N, Tongs C. Treatment of human blood during extracorporeal circulation using a gas exchange device (GED) in patients. US Patent 60/977,149, October 13th 2007.
69. Di Paolo N, Bocci V, Salvo DP, et al. Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. Int J Artif Organs 2005; 28: 1039-50.
70. Wenzel RP, Edmond MB. The evolving technology of venous access. N Engl J Med 1999; 340: 48-50.
71. Bergqvist D. Salvage of critically ischaemic limbs. Lancet 1999; 354: 1920-1.
72. Lu XW, Idu MM, Ubbink DT, Legemate DA. Meta-analysis of the clinical effectiveness of venous arterialization for salvage of critically ischaemic limbs. Eur J Vasc Endovasc Surg 2006; 31: 493-9.
73. Kang N, Jackson WA, Dasgupta PK, Anderson TA. Perchlorate production by ozone oxidation of chloride in aqueous and dry systems. Sci Total Environ 2008; 405: 301-9.
74. 2. Water Res 2004; 38: 2383-93.
75. Goldmann BU, Rudolph V, Rudolph TK, et al. Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction. Free Radic Biol Med 2009, in press. DOI:10.1016/j.freeradbiomed.2009.04.004.
76. Ikonomidis S, Tsaousis P, Fyntanis A, Iliakis EM. New data regarding the use of oxidative stress (ozone therapy) in the former Soviet Union Countries. Rivista Italiana di Ossigeno-Ozonoterapia 2005; 4: 40-3.
77. Bocci V, Aldinucci C, Bianchi L. The use of hydrogen peroxide as a medical drug Rivista Italiana di Ossigeno-Ozonoterapia 2005; 4: 30-9.
78. Barco G. Un caso di linfoma non-Hodgkin non responsivo alle comuni terapie e trattato con ossigeno poliatomico liquido (OPL) somministrato in continuo per via venosa centrale e temozolomide. Int J Ozone Ther 2007; 6: 157-62.
79. Cacace F, De Petris G, Troiani A. Experimental detection of tetraoxygen. Angew Chem Int Ed Engl 2001; 40: 4062-5.
80. Ball P. New form of oxygen found. Nat News 2001; DOI:10.1038/news011122- 3.
81. Matejcik S, Cicman P, Kiendler A, et al. Low-energy electron attachment to mixed ozone/oxygen clusters. Chem Phys Lett 1999; 261: 437-42.
82. 9. Ozone: Sci Eng 2003; 25: 211-21.
83. Viebahn-Hänsler R. Allgemeine Eigenschaften des Ozons. In: Viebahn-Hänsler R, Knoch HG Eds, Ozon-Handbuch. Grundlagen. Prävention. Therapie. Kaufbeuren, Ecomed Verlagsgesellschaft 2001; II-1.1: 1-14.
84. Belianin II, Abdullaev RIu. Use of soluble ozone in combined treatment of pulmonary tuberculosis: lipid peroxidation and blood antioxidative defense systems. Probl Tuberk 2000; 3: 41-4.
85. Michaeli D, Michaeli M. Improved radial expansible retractor for minimally invasive surgery. PCT application number WO 2007/069232.
86. Travagli V, Zanardi I, Bocci V. Topical applications of ozone and ozonated oils as anti-infective agents: an insight into the patent claims. Recent Pat Anti Infect Drug Discov 2009, in press.
87. Sweet F, Kao MS, Lee SC, Hagar WL, Sweet WE. Ozone selectively inhibits growth of human cancer cells. Science 1980; 209: 931-3.
88. Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007; 25: 2288-94.
89. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 2008; 20: 267-75.
90. Lynch E. Evidence-based efficacy of ozone for root canal irrigation. J Esthet Restor Dent 2008; 20: 287-93.
91. Loncar B, Stipetic MM, Matosevic D, Tarle Z. Ozone application in dentistry. Arch Med Res 2009; 40: 136-7.
92. Bocci V, Borrelli E, Valacchi G, Luzzi E. Quasi-total-body exposure to an oxygen-ozone mixture in a sauna cabin. Eur J Appl Physiol Occup Physiol 1999; 80: 549-54.
93. He QC, Tavakkol A, Wietecha K, Begum-Gafur R, Ansari SA, Polefka T. Effects of environmentally realistic levels of ozone on stratum corneum function. Int J Cosmet Sci 2006; 28: 349-57.
94. Bocci V. Quasi-total body exposure to oxygen-ozone. In: Ozone. A new medical drug. Dordrecht, The Netherlands, Springer 2005; 56-65.
95. Bocci V. The paradoxical effect of ozone in orthopaedic diseases. The problem of back-ache. In: Ozone. A new medical drug. Dordrecht, The Netherlands, Springer 2005; 198-208.
96. Kakigi R, Inui K, Tamura Y. Electrophysiological studies on human pain perception. Clin Neurophysiol 2005; 116: 743-63.
97. Gallucci M, Puglielli E, Splendiani A, Pistoia F, Spacca G. Degenerative disorders of the spine. Eur Radiol 2005; 15: 591-8.
98. Rathmell JP. A 50-year-old man with chronic low back pain. JAMA 2008; 299: 2066-77.
99. Samanta A, Beardsley J. Low back pain: which is the best way forward. BMJ 1999; 318: 1122-3.
100. McCord JM. Free radicals and inflammation: protection of synovial fluid by superoxide dismutase. Science 1974; 185: 529-31.
101. Curran SF, Amoruso MA, Goldstein BD, Berg RA. Degradation of soluble collagen by ozone or hydroxyl radicals. FEBS Lett 1984; 176: 155-60.
102. Ueno I, Hoshino M, Miura T, Shinriki N. Ozone exposure generates free radicals in the blood samples in vitro. Detection by the ESR spin-trapping technique. Free Radic Res 1998; 29: 127-35.
103. Bocci V, Pogni R, Corradeschi F, et al. Oxygen-ozone in orthopaedics: EPR detection of hydroxyl free radicals in ozone-treated "nucleus pulposus" material. Riv Neuroradiol 2001; 14: 55-9.
104. Halliwell B. Free radicals and antioxidants: a personal view. Nutr Rev 1994; 52: 253-65.
105. 3 intradiscale. In Proceedings: I Congresso IMOS, Italia, Siena, 2-4 novembre 2000; pp.7-8.
106. Silver FH, Glasgold AI. Cartilage wound healing. An overview. Otolaryngol Clin North Am 1995; 28: 847-64; Trippel SB. Growth factor actions on articular cartilage. J Rheumatol 1995; 43: 129-32.
107. Borrelli E, Bocci V. Basic biological and therapeutic effects of ozone therapy in human medicine. In: Munter R Ed, Ozone Science and Technology, in Encyclopedia of Life Support Systems. Oxford, Eolss Publisher 2008.
108. Fabris G, Tommasini G, Petralia B, et al. L'ossigeno-ozono terapia intra-foraminale. Riv Neuroradiol 2001; 14: 61-6.
109. Alexandre A, Pentimalli L, Rigobello L, Corò N. In: Ceccherelli F, Giron F, Eds, L'Ozonoterapia nel 2000. Torino, Edizioni Libreria Cortina 2000; 141-4.
110. Pellicanò G, Martinelli F, Tavanti V, et al. The Italian Oxygenozone therapy Federation (FIO) study on oxygen-ozone treatment of herniated disc. Intern J Ozone Ther 2007; 6: 7-15.
111. 3 infiltration for symptomatic herniated disc refractory to conventional treatment. A prospective randomized study. Riv It Ossigeno-Ozonoterapia 2006; 5: 123-27.
112. Gallucci M, Limbucci N, Zugaro L, et al. Sciatica: treatment with intradiscal and intraforaminal injections of steroid and oxygenozone versus steroid only. Radiology 2007; 242: 907-13.
113. Schulz S, Häussler U, Mandic R, et al. Treatment with ozone/oxygen-pneumoperitoneum results in complete remission of rabbit squamous cell carcinomas. Int J Cancer 2008; 122: 2360-7.
114. Bocci V. Does ozone really "cure" cancer? Int J Cancer 2008; 123: 1222.
115. Bocci V. Ozone therapy in cancer. In: Ozone. A new medical drug. Dordrecht, The Netherlands, Springer 2005; 162-175.
116. Bocci V. Rectal insufflation of oxygen-ozone. In: Ozone. A new medical drug. Dordrecht, The Netherlands, Springer 2005; 49-56.
117. Bocci V, Borrelli E, Corradeschi F, Valacchi G. Systemic effects after colorectal insufflation of oxygen-ozone in rabbits. Int J Med Biol Environ 2000; 28: 109-13.
118. Kulikov AG, Turova EA, Shcherbina TM, Kisileva OM. Efficacy of different methods of ozone therapy in vascular complication of diabetes mellitus. Vopr Kurortol Fizioter Lech Fiz Kult 2002; 5: 17-20.
119. Hernández Rosales FA, Calunga Fernández JL, Turrent Figueras J, Menéndez Cepero S, Montenegro Perdomo A. Ozone therapy effects on biomarkers and lung function in asthma. Arch Med Res 2005; 36: 549-54.
120. Martínez-Sánchez G, Al-Dalain SM, Menéndez S, et al. Therapeutic efficacy of ozone in patients with diabetic foot. Eur J Pharmacol 2005; 523: 151-61.
121. León Fernández OS, Ajamieh HH, Berlanga J, et al. Ozone oxidative preconditioning is mediated by A1 adenosine receptors in a rat model of liver ischemia/reperfusion. Transpl Int 2008; 21: 39-48.